Mok Dae-gyun

The company should be held long-term as the massive potential value of its autonomous driving, Optimus humanoid robots, and synergies with SpaceX are not yet fully reflected in the current stock price.

SK Hynix is trading at only 4.5x PE, implying either a dramatic halving of earnings or extreme undervaluation. Given tight memory supply until at least 2027-2028, resilient HBM demand, and the company's shift to long-term agreements (LTA) that reduce earnings volatility and provide stable pricing, the earnings collapse scenario is unlikely. The recent 20% drop is overdone, and current levels represent an attractive entry for medium-term investors. The speaker expresses a desire to cautiously buy.

Samsung Electronics, alongside SK Hynix, is trading at an extremely low 4-4.5x PE multiple, far below historical norms. While the discussion lacks additional Samsung-specific catalysts, the extreme valuation cheapness and the ongoing memory upcycle support a buying opportunity, assuming earnings do not collapse.

KOSPI is trading at a 5x PE ratio, far below its historical average of around 10x, indicating deep undervaluation. Despite short-term downside momentum driven by panic, leverage unwinds, and supply/demand imbalances, underlying corporate earnings remain intact. Over a 6- to 12-month horizon, current levels present a favorable entry point with a high probability of positive returns, assuming earnings do not collapse. The sell-off is exaggerated relative to fundamentals.

US pharmaceutical stocks offer a defensive rotation opportunity. After being beaten down, they appear undervalued and can act as a volatility hedge when semiconductor names become overextended. If interest rates rise, pharma stocks benefit from the defensive tilt, and institutional investors have already been adding exposure and even buying call options on the sector as a portfolio buffer.